Mateusz Kaczmarek, Author at TechStock²

Qualys (QLYS) Today — Nov 8, 2025: Analyst Upgrade Follows Q3 Beat; Guidance Raised as Stock Hovers Near $150

Qualys, Inc. (NASDAQ: QLYS) is ending the week with fresh analyst attention after posting a stronger‑than‑expected third quarter and raising full‑year guidance earlier this week. As of today, one outlet reports an upgrade to Buy while another highlights lifted EPS

8 November 2025

Analyst Ratings·Earnings Reports·Financial News·Stock Market·Technology Stocks

CAVA Stock News Today (Nov 8, 2025): Guidance Cut Fallout, Analyst Target Resets, and What’s Next for CAVA Group (NYSE: CAVA)

This week at a glance: why CAVA is in the headlines Analyst moves since the print These updates follow earlier, more bullish initiations earlier in the year, underscoring how quickly sentiment has cooled as traffic moderates. Investopedia By the numbers

8 November 2025

Analyst Insights·Financial News·Investment Strategies·Stock Market

Sling TV adds 159,000 subscribers in Q3 2025 as $4.99 Day/Weekend/Week Passes and new $19.99 “Select” tier drive ~11% sequential growth

Why Sling is growing again Sling TV put points on the board in Q3 2025, logging approximately 159,000 net subscriber additions—a turnaround after earlier‑year declines. EchoStar’s Pay‑TV unit (DISH + Sling) closed the quarter with ~7.17 million customers, while the

8 November 2025

Streaming

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer Inc. (NYSE: PFE) has secured a definitive agreement to acquire weight‑loss biotech Metsera in a transaction valued at up to $10 billion, ending a high‑stakes bidding war with Novo Nordisk and positioning Pfizer squarely back in the fast‑growing obesity

8 November 2025

Business News·Healthcare Industry·Mergers & Acquisitions·Pharmaceuticals

Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer sealed a deal to acquire Metsera for up to $10 billion, ending one of 2025’s fiercest pharma bidding wars and reshaping the obesity‑drug race. Below are the facts, context, and what’s next for MTSR shareholders and the GLP‑1 landscape.

8 November 2025

Healthcare Industry·Investment News·Mergers & Acquisitions·Pharmaceuticals·Stock Market

EOSE News Today (Nov 8, 2025): Analyst Downgrade Caps Volatile Week After Record Q3; Warrants Jump as New Orders Build

Eos Energy Enterprises, Inc. (NASDAQ: EOSE) closed out a whipsaw week with fresh weekend headlines: an analyst downgrade, a small fund trimming its position, and continued attention on the company’s Q3 results and growing long‑duration storage pipeline. Below is a

8 November 2025

Earnings Reports·Financial News·Investment Insights·Market Analysis·Stock Updates

Today in Airline Routes (Nov. 8, 2025): Breeze enters Twin Falls; JetBlue targets Destin–Fort Walton; Spirit lands in Key West — plus key global moves

Breeze Airways is continuing its “underserved markets” strategy with a fresh round of growth for spring 2026 — and a brand‑new dot on its map: Twin Falls, Idaho (TWF). Starting March 6, 2026, Breeze will fly nonstop Twin Falls–Las Vegas

8 November 2025

Industry Trends

SPY Holds the $667 Line as AI CapEx Booms and Fed Officials Cloud a December Cut — Weekend Market Wrap (Nov. 8, 2025)

What moved stocks on Friday Stocks whipsawed but the S&P 500 and Dow finished slightly higher, while the Nasdaq slipped amid renewed skepticism about the durability of the AI rally. Late‑day reports of shutdown progress helped narrow losses. Treasury 10‑year

8 November 2025

AI Investments·Economic Analysis·Federal Reserve·Market Trends·Stock Market

Conduent (CNDT) Q3 2025 Earnings: Revenue Misses at $767M as Adjusted EBITDA Margin Climbs to 5.2%; FY 2025 Margin Outlook 5.0%–5.5%, Shares Slide

Conduent Incorporated (NASDAQ: CNDT) reported third‑quarter 2025 revenue of $767 million (down 5% YoY) and Adjusted EBITDA of $40 million with a 5.2% margin, reflecting continued cost discipline even as top‑line pressure persisted. Management reiterated a full‑year 2025 Adjusted EBITDA

8 November 2025

Business Analysis·Corporate News·Earnings Reports·Financial Results·Stock Market

VTI vs. VOO on November 7, 2025: Daily Update, Flows & Why Vanguard’s Flagship ETFs Still Dominate With Young Investors

What changed today (Nov. 7, 2025) Fresh data from TipRanks’ “VTI ETF Daily Update — 11/7/2025” shows the Vanguard Total Stock Market ETF (VTI) slipped 1.17% on Thursday, part of a −2.72% five‑day stretch, while YTD returns remain +14.71%. Despite

7 November 2025

ETFs·Investing·Market Updates·Personal Finance

Fluor (FLR) Q3 2025: Adjusted EPS Beats, Guidance Raised; $800M Buyback Target and NuScale Monetization Drive Outlook

What Fluor reported today Fluor Corporation released third‑quarter 2025 results before the market open. Headline items: Segment color. Strategy & capital allocation updates How the market is reacting today FLR traded sharply higher out of the gate before retracing; intraday

7 November 2025

Company Analysis·Earnings Reports·Investment Strategies·Stock Market News

Franklin Resources (BEN) Q4 FY2025: Adj. EPS $0.67 Beats, Revenue $2.34B; AUM $1.66T as Ex‑Western Inflows Climb

Franklin Resources, Inc. (NYSE: BEN), the parent of Franklin Templeton, reported preliminary fiscal Q4 2025 results before the bell Friday, posting GAAP revenue of $2.34 billion and adjusted diluted EPS of $0.67, topping pre‑earnings consensus that had centered around $0.57

7 November 2025

Earnings Reports·Financial Results·Market Analysis